The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
The Manila Times17h
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million; GraftAssure RUO assay launched July ...
BMJ16h
How to increase value and reduce waste in research: initial experiences of applying Lean thinking and visual management in research leadership
In the university hospital’s 2021–2025 research strategy, goals and actions were specified for a 5-year period for value-creating key behavioural and key performance measurements (table 1). Working ...